Nothing Special   »   [go: up one dir, main page]

WO2002068389A3 - Indole derivatives with inhibitor effects on phenol oxidase - Google Patents

Indole derivatives with inhibitor effects on phenol oxidase Download PDF

Info

Publication number
WO2002068389A3
WO2002068389A3 PCT/EP2002/001920 EP0201920W WO02068389A3 WO 2002068389 A3 WO2002068389 A3 WO 2002068389A3 EP 0201920 W EP0201920 W EP 0201920W WO 02068389 A3 WO02068389 A3 WO 02068389A3
Authority
WO
WIPO (PCT)
Prior art keywords
indole derivatives
melassezia
yeast
melanin
substances
Prior art date
Application number
PCT/EP2002/001920
Other languages
German (de)
French (fr)
Other versions
WO2002068389A2 (en
Inventor
Peter Mayser
Wolfgang Steglich
Hans-Joachim Kraemer
Bernhard Irlinger
Original Assignee
Peter Mayser
Wolfgang Steglich
Hans-Joachim Kraemer
Bernhard Irlinger
Bayern Freistaat
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Peter Mayser, Wolfgang Steglich, Hans-Joachim Kraemer, Bernhard Irlinger, Bayern Freistaat filed Critical Peter Mayser
Priority to AU2002233359A priority Critical patent/AU2002233359A1/en
Publication of WO2002068389A2 publication Critical patent/WO2002068389A2/en
Publication of WO2002068389A3 publication Critical patent/WO2002068389A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to indole derivatives having an inhibiting effect on phenol oxidases. Melanin-related hyperpigmentation of skin is a considerable medical and therapeutic problem. The current possibilities for therapeutic effects, in addition to invasive methods, particularly the insertion of decolorants, are limited. The invention also relates to the increased need for agents and substances for treating melanin-related hyperpigmentation. The amino acid tryptophane (as an L or D isomer or also as a racemate) is provided for a particular subpopulation of the yeast type Melassezia, particularly the yeast species Melassezia furfur, as a predominant nitrogen source, and compounds are isolated from the yeast conditioned in such a manner, said compounds represent potent inhibitors of phenol oxidases. The novel indole derivatives isolated from Melassezia is particularly suitable to be used as substances for producing medicaments for treating melanin-related hyperpigmentation.
PCT/EP2002/001920 2001-02-23 2002-02-23 Indole derivatives with inhibitor effects on phenol oxidase WO2002068389A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2002233359A AU2002233359A1 (en) 2001-02-23 2002-02-23 Indole derivatives with inhibitor effects on phenol oxidase

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10109005.6 2001-02-23
DE10109005A DE10109005A1 (en) 2001-02-23 2001-02-23 Indole derivatives with an inhibitory effect on phenol oxidases

Publications (2)

Publication Number Publication Date
WO2002068389A2 WO2002068389A2 (en) 2002-09-06
WO2002068389A3 true WO2002068389A3 (en) 2002-12-12

Family

ID=7675398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/001920 WO2002068389A2 (en) 2001-02-23 2002-02-23 Indole derivatives with inhibitor effects on phenol oxidase

Country Status (3)

Country Link
AU (1) AU2002233359A1 (en)
DE (1) DE10109005A1 (en)
WO (1) WO2002068389A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8493081B2 (en) 2009-12-08 2013-07-23 Magna Closures Inc. Wide activation angle pinch sensor section and sensor hook-on attachment principle
US9234979B2 (en) 2009-12-08 2016-01-12 Magna Closures Inc. Wide activation angle pinch sensor section
CN113698336B (en) 2016-03-10 2024-02-13 弗西科勒技术有限责任公司 Malachicaine and analogues thereof as skin whitening agents

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
MAYSER, P ET AL: "Synthesis of fluorochromes and pigments in Malassezia furfur by use of tryptophane as the single nitrogen source", MYCOSES, vol. 41, 1998, pages 265 - 271, XP002199623 *
MAYSER, P. ET AL.: "Synthese von Fluorochromen und Pigmenten durch Malassezia furfur unter Verwendung von Tryptophan als alleiniger Stickstoffquelle", MYCOSES, vol. 41, no. suppl. 2, 1998, pages 74 - 77, XP001079243 *
WILLE, G.: "Synthese und Strukturaufklärung von Sekundärmetaboliten aus Schleimpilzen und lipophilen Hefen", 2000, WWW.DISSERTATION.DE, BERLIN; ISBN 3-89825-074-1, XP002199624 *

Also Published As

Publication number Publication date
AU2002233359A1 (en) 2002-09-12
DE10109005A1 (en) 2002-09-05
WO2002068389A2 (en) 2002-09-06

Similar Documents

Publication Publication Date Title
EP1485381B8 (en) Azolylaminoazine as inhibitors of protein kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2003089456A3 (en) Peptide inhibitors of protein kinase c
WO1999043651A3 (en) Inhibitors of phospholipase enzymes
EP1353684B8 (en) Use of inhibitors of dipeptidypeptidase iv (ec 3.3.14.5) and aminopeptidase n (ec 3.4.11.2) for the treatment of neurodegeneration induced by ischaemia
WO2000040235A3 (en) Treatment of asthma with mek inhibitors
MY119231A (en) Novel lipoic acid derivatives, their preparation, and pharmaceutical compositions containing them
WO2005028475A3 (en) Compositions useful as inhibitors of protein kinases
WO2004056307A3 (en) Disease treatment via antimicrobial peptide inhibitors
WO2005000213A3 (en) Method for treating diseases using HSP90-inhibiting agents in combination with enzyme inhibitors
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
WO2003024386A3 (en) Use of potent, selective and non toxic c-kit inhibitors for treating interstitial cystitis
WO2003048122A3 (en) Inhibitors of cytosolic phospholipase a2
WO2005014572A8 (en) Pyrimidylpyrrole derivatives active as kinase inhibitors
WO2004052236A3 (en) Methods and compositions for treatment of otitis media
WO2005018535A3 (en) Compositions and methods for treatment of severe acute respiratory syndrome (sars)
WO2002094189A3 (en) Compositions and methods for treating or preventing convulsions or seizures
HK1086548A1 (en) Deuterated catecholamine derivatives and medicaments comprising said compounds
WO2001030331A3 (en) Therapeutic compositions including protein kinase c inhibitors
AU3864000A (en) Inhibitors of serine protease activity, methods and compositions for treatment of herpes viruses
WO2002068389A3 (en) Indole derivatives with inhibitor effects on phenol oxidase
WO2003051838A3 (en) Protein kinase inhibitors
WO2003072537A3 (en) Selective protein tyrosine phosphatatase inhibitors

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP